Ramin Nourinia1, Mozhgan Rezaei Kanavi1, Amir Kaharkaboudi1, Seyed Iman Taghavi2, Seyed Javid Aldavood2, Soesiawati R Darjatmoko3, Shoujian Wang3, Zafer Gurel3, Jeremy A Lavine3, Sare Safi1, Hamid Ahmadieh4, Narsis Daftarian1, Nader Sheibani5. 1. Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. 3. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States. 4. Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States 5McPherson Eye Research Institute, University Wisconsin School of Medicine and Public Health, Madison, Wiscons.
Abstract
PURPOSE: Determine the safe dose of intravitreal propranolol (IVP), and evaluate its inhibitory effect on laser-induced choroidal neovascularization (CNV). METHODS: To determine the IVP safe dose, 32 rabbits were divided into 4 groups. Three of these groups received IVP (15 μL) corresponding to 15 μg (group B), 30 μg (group C), and 60 μg (group D). The control group (A) received 15 μL saline. Safety was assessed by ocular examination, electroretinography (ERG), routine histopathologic evaluation, immunohistochemistry for glial fibrillary acidic protein (GFAP), and real-time qPCR for GFAP, VEGF, thrombospondin 1 (TSP1), and pigment epithelium-derived factor (PEDF). A similar experiment was performed in 24 mice by using a 100-fold lower amount of propranolol (0.15, 0.3, and 0.6 μg in 2 μL) based on vitreous volume. For assessment of the angioinhibitory effects of IVP, CNV was induced in 42 mice via laser burns. Mice were divided into two groups: group 1 received the safe dose of IVP (0.3 μg in 2 μL) and group 2 received saline. Neovascularization area was quantified by intercellular adhesion molecule (ICAM)-2 immunostaining of choroidal-scleral flat mounts by using ImageJ software. RESULTS: According to clinical, ERG, and histopathologic findings, 30 μg IVP was chosen as the safe dose in rabbit eyes, comparable to 0.3 μg IVP in mouse eyes. As compared to the control eyes, the development of CNV was attenuated (4.8-fold) in mice receiving 0.3 μg IVP. CONCLUSIONS: Intravitreal propranolol injection up to the final dose of 30 μg in rabbits and 0.3 μg in mice was safe, and was effective in attenuation of CNV in mice.
PURPOSE: Determine the safe dose of intravitreal propranolol (IVP), and evaluate its inhibitory effect on laser-induced choroidal neovascularization (CNV). METHODS: To determine the IVP safe dose, 32 rabbits were divided into 4 groups. Three of these groups received IVP (15 μL) corresponding to 15 μg (group B), 30 μg (group C), and 60 μg (group D). The control group (A) received 15 μL saline. Safety was assessed by ocular examination, electroretinography (ERG), routine histopathologic evaluation, immunohistochemistry for glial fibrillary acidic protein (GFAP), and real-time qPCR for GFAP, VEGF, thrombospondin 1 (TSP1), and pigment epithelium-derived factor (PEDF). A similar experiment was performed in 24 mice by using a 100-fold lower amount of propranolol (0.15, 0.3, and 0.6 μg in 2 μL) based on vitreous volume. For assessment of the angioinhibitory effects of IVP, CNV was induced in 42 mice via laser burns. Mice were divided into two groups: group 1 received the safe dose of IVP (0.3 μg in 2 μL) and group 2 received saline. Neovascularization area was quantified by intercellular adhesion molecule (ICAM)-2 immunostaining of choroidal-scleral flat mounts by using ImageJ software. RESULTS: According to clinical, ERG, and histopathologic findings, 30 μg IVP was chosen as the safe dose in rabbit eyes, comparable to 0.3 μg IVP in mouse eyes. As compared to the control eyes, the development of CNV was attenuated (4.8-fold) in mice receiving 0.3 μg IVP. CONCLUSIONS: Intravitreal propranolol injection up to the final dose of 30 μg in rabbits and 0.3 μg in mice was safe, and was effective in attenuation of CNV in mice.
Authors: Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb Journal: N Engl J Med Date: 2008-06-12 Impact factor: 91.245
Authors: H G Blaauwgeers; G M Holtkamp; H Rutten; A N Witmer; P Koolwijk; T A Partanen; K Alitalo; M E Kroon; A Kijlstra; V W van Hinsbergh; R O Schlingemann Journal: Am J Pathol Date: 1999-08 Impact factor: 4.307
Authors: Mingkai Lin; Yang Hu; Ying Chen; Kevin K Zhou; Ji Jin; Meili Zhu; Yun-Zheng Le; Jian Ge; Jian-Xing Ma Journal: Invest Ophthalmol Vis Sci Date: 2012-09-14 Impact factor: 4.799
Authors: Jeremy A Lavine; Mitra Farnoodian; Shoujian Wang; Soesiawati R Darjatmoko; Lynda S Wright; David M Gamm; Michael S Ip; Christine M Sorenson; Nader Sheibani Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799
Authors: Mohammad R Talebnejad; Ali Sadeghi-Sarvestani; M Hossein Nowroozzadeh; Seyed Mohammad J Mortazavi; Abbas Alighanbari; Mohammad R Khalili Journal: J Curr Ophthalmol Date: 2017-10-09
Authors: Beatriz González-Rodríguez; Karina Villar Gómez de Las Heras; Daniel T Aguirre; Luis Rodríguez-Padial; Virginia Albiñana; Lucía Recio-Poveda; Angel M Cuesta; Luisa Mª Botella; Rosa María Jiménez-Escribano Journal: BMJ Open Ophthalmol Date: 2019-05-28